曲妥珠单抗联合新辅助化疗对HER-2阳性乳腺癌患者近远期疗效的影响

Efficacy of Trastuzumab Joint Neoadjuvant Chemotherapy for HER-2 Positive Breast Cancer

目的探讨曲妥珠单抗联合新辅助化疗对表皮生长因子受体-2(HER-2)阳性乳腺癌患者的疗效。方法选取HER-2阳性乳腺癌患者58例,随机分为观察组和对照组,各29例。对照组给予表柔比星联合多西他赛的方案进行新辅助化疗,观察组在对照组的基础上给予曲妥珠单抗治疗。比较两组患者的近期、远期疗效。结果观察组有效率(RR)及病理完全缓解(p CR)率明显优于对照组,5年总生存率(OS)及5年无病生存率(DFS)明显高于对照组。结论曲妥珠单抗联合新辅助化疗治疗HER-2阳性乳腺癌近期疗效显著,并可有效改善患者预后,值得临床推广应用。

Objective To investigate the efficacy of trastuzumab joint neoadjuvant chemotherapy for hers-2 positive breast cancer. Methods 58 hers-2 positive breast cancer patients were randomly divided into the observation group and the con- trol group, each with 29 cases. The control group was given epirubicin combined with docetaxel neoadjuvant chemotherapy, the ob- servation group on the basis of the control group was given trastuzumab. Short-term and long-term efficacy of the 2 groups were compared. Results Efficient （RR） and pathological complete response （pCR） rate of the observation group were significantly better than those of the control group ,the 5-year overall survival （OS） and 5-years disease-free survival （DFS） were significantly higher than those of the control group. Conclusion Trastuzumab joint neoadjuvant chemotherapy for hers-2 positive breast cancer has significant short-term efficacy, and can effectively improve the prognosis of patients, it is worthy of clinical popularization and application.